Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings

被引:91
作者
Bestvina, Christine M. [1 ]
Fleming, Gini F. [1 ]
机构
[1] Univ Chicago, 5841 S Maryland Ave, Chicago, IL 60637 USA
关键词
Chemoradiotherapy; Drug therapy; adjuvant; Endometrial cancer; Local neoplasm recurrence; Metastasis; neoplasm; PHASE-II TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; PACLITAXEL PLUS FILGRASTIM; ONCOLOGY-GROUP; RADIATION-THERAPY; MEGESTROL-ACETATE; MEDROXYPROGESTERONE ACETATE; 1ST-LINE CHEMOTHERAPY; 2ND-LINE CHEMOTHERAPY; INTERMEDIATE-RISK;
D O I
10.1634/theoncologist.2016-0062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Level I evidence exists for use of adjuvant chemotherapy in stage IIIC endometrial cancer (positive lymph nodes), although results of randomized trials have varied. Chemotherapy is also often recommended for high-risk subsets of stage I disease, such as serous carcinomas, although prospective trial data to validate this practice are lacking. Carboplatin plus paclitaxel is the current standard regimen, based on extrapolation of data from the metastatic setting. Several clinical trials have compared adjuvant pelvic radiotherapy alone to a combination of radiotherapy and chemotherapy with mixed results. One of the largest of these trials, Postoperative Radiation Therapy in Endometrial Carcinoma 3 (PORTEC-3), has completed accrual and is awaiting data maturation. Metastatic disease is not curable. For tumors of low-grade endometrioid histology with a prolonged time to recurrence, endocrine therapy with a progestin-based regimen is appropriate. Chemotherapy will be used in most other cases, and the standard first-line regimen is carboplatin and paclitaxel. Few chemotherapy agents have been shown to produce meaningful response rates in the second-line setting. Molecularly targeted therapies such as m TOR inhibitors and antiangiogenic agents including bevacizumab have been studied but their role in the armamentarium remains uncertain.
引用
收藏
页码:1250 / 1259
页数:10
相关论文
共 105 条
[1]   Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group [J].
Aapro, MS ;
van Wijk, FH ;
Bolis, G ;
Chevallier, B ;
van der Burg, MEL ;
Poveda, A ;
de Oliveira, CF ;
Tumolo, S ;
di Palumbo, VS ;
Piccart, M ;
Franchi, M ;
Zanaboni, F ;
Lacave, AJ ;
Fontanelli, R ;
Favalli, G ;
Zola, P ;
Guastalla, JP ;
Rosso, R ;
Marth, C ;
Nooij, M ;
Presti, M ;
Scarabelli, C ;
Splinter, TAW ;
Ploch, E ;
Beex, LVA ;
Huinink, WT ;
Forni, M ;
Melpignano, M ;
Blake, P ;
Kerbrat, P ;
Mendiola, C ;
Cervantes, A ;
Goupil, A ;
Harper, PG ;
Madronal, C ;
Namer, M ;
Scarfone, G ;
Stoot, JEGM ;
Teodorovic, I ;
Coens, C ;
Vergote, I ;
Vermorken, JB .
ANNALS OF ONCOLOGY, 2003, 14 (03) :441-448
[2]   Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study [J].
Aghajanian, Carol ;
Sill, Michael W. ;
Darcy, Kathleen M. ;
Greer, Benjamin ;
McMeekin, D. Scott ;
Rose, Peter G. ;
Rotmensch, Jacob ;
Barnes, Mack N. ;
Hanjani, Parviz ;
Leslie, Kimberly K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2259-2265
[3]   Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study [J].
Alvarez, Edwin A. ;
Brady, William E. ;
Walker, Joan L. ;
Rotmensch, Jacob ;
Zhou, Xun C. ;
Kendrick, James E. ;
Yamada, S. Diane ;
Schilder, Jeanne M. ;
Cohn, David E. ;
Harrison, Charles R. ;
Moore, Kathleen N. ;
Aghajanian, Carol .
GYNECOLOGIC ONCOLOGY, 2013, 129 (01) :22-27
[4]   Cancer of the corpus uteri [J].
Amant, Frederic ;
Mirza, Mansoor Raza ;
Koskas, Martin ;
Creutzberg, Carien L. .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2015, 131 :S96-S104
[5]  
[Anonymous], PREV VERS SEER CANC
[6]   Goserelin acetate as treatment for recurrent endometrial carcinoma - A gynecologic oncology group study [J].
Asbury, RF ;
Brunetto, VL ;
Lee, RB ;
Reid, G ;
Rocereto, TF .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06) :557-560
[7]   Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].
Baselga, Jose ;
Campone, Mario ;
Piccart, Martine ;
Burris, Howard A., III ;
Rugo, Hope S. ;
Sahmoud, Tarek ;
Noguchi, Shinzaburo ;
Gnant, Michael ;
Pritchard, Kathleen I. ;
Lebrun, Fabienne ;
Beck, J. Thaddeus ;
Ito, Yoshinori ;
Yardley, Denise ;
Deleu, Ines ;
Perez, Alejandra ;
Bachelot, Thomas ;
Vittori, Luc ;
Xu, Zhiying ;
Mukhopadhyay, Pabak ;
Lebwohl, David ;
Hortobagyi, Gabriel N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529
[8]   A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study [J].
Bender, David ;
Sill, Michael W. ;
Lankes, Heather A. ;
Reyes, Henry D. ;
Darus, Christopher J. ;
Delmore, James E. ;
Rotmensch, Jacob ;
Gray, Heidi J. ;
Mannel, Robert S. ;
Schilder, Jeanne M. ;
Hunter, Mark I. ;
McCourt, Carolyn K. ;
Samuelson, Megan I. ;
Leslie, Kimberly K. .
GYNECOLOGIC ONCOLOGY, 2015, 138 (03) :507-512
[9]   A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia [J].
Castonguay, Vincent ;
Lheureux, Stephanie ;
Welch, Stephen ;
Mackay, Helen J. ;
Hirte, Hal ;
Fleming, Gini ;
Morgan, R. ;
Wang, Lisa ;
Blattler, Chantale ;
Ivy, Percy S. ;
Oza, Amit M. .
GYNECOLOGIC ONCOLOGY, 2014, 134 (02) :274-280
[10]  
*CLIN, EV CARB PACL TRAST H